argatroban
Approved
Jun 30, 2000
Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 µM. At therapeutic concentrations, Argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein). Argatroban is capable of inhibiting the action of both free and clot-associated thrombin. Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is indicated as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI). — NCATS
Clinical trial activity
28 trials · 27 clinical orgs · 22 marketing orgs
Earliest trial started May 1, 2002 (NCT00035178)
Timeline
2000s
2010s
- Jul 28, 2010
Baxalta — NDA Secondary Org
- Dec 29, 2010
Pliva — Marketing Organization
- Dec 29, 2010
Teva — Marketing Organization
- May 9, 2011
Sandoz — NDA Secondary Org
- Jun 29, 2011
Cipla — Marketing Organization
- Jun 29, 2011
Eagle Pharmaceuticals, Inc. — NDA Secondary Org
- Jun 29, 2011
Cipla — NDA Secondary Org
- Jan 5, 2012
Hikma — NDA Secondary Org
- Jun 30, 2014
Endo Pharmaceuticals — Marketing Organization
- Jun 30, 2014
Mylan — Marketing Organization
- Jun 30, 2014
Par Pharmaceuticals — Marketing Organization
- Dec 15, 2014
Teva — NDA Secondary Org
- Mar 23, 2015
Fresenius — NDA Secondary Org
- Sep 21, 2016
Hospira — Marketing Organization
- Sep 21, 2016
Pfizer — Marketing Organization
- May 22, 2017
Gland Pharma Ltd — Marketing Organization
- Jan 26, 2018
Amneal Pharmaceuticals — Marketing Organization
- Nov 27, 2018
Aurobindo Pharma — NDA Secondary Org
- Nov 27, 2018
Eugia Pharma — Marketing Organization
- Nov 27, 2018
Eugia Pharma — NDA Secondary Org
2020s
- Jan 21, 2021
Caplin Point Laboratories — Marketing Organization
- Jun 7, 2021
Accord Research — Marketing Organization
- Jun 7, 2021
Accord Research — NDA Secondary Org
- Jul 31, 2023
Fosun — Marketing Organization
Indications
Approved for
Studied for
- Angina, Unstable · Phase 4
- Anticoagulants · Phase 2/Phase 3
- Blood Platelets · Phase 4
- Brain Ischemia · Phase 2
- Coronary Artery Disease · Phase 2
- Coronary Disease · Phase 4
- COVID-19 · Phase 4
- Drugs, Investigational · Phase 4
- Extracorporeal Membrane Oxygenation · Phase 2/Phase 3
- General Surgery · Phase 4
- Genital Neoplasms, Female · Phase 3
- Heart Diseases · Phase 4
- Hemorrhage · Phase 4
- Heparin, Low-Molecular-Weight · Phase 3
- Ischemic Stroke · Phase 4
- Kidney Failure, Chronic · Phase 4
- Respiratory Insufficiency · Phase 4
- Shock · Phase 4
- Staphylococcal Infections · Phase 2
- Stroke · Phase 4
- Thromboembolism · Phase 4
- Thrombosis · Phase 4
- Venous Thromboembolism · Phase 3
Mechanism of action
- ThrombinINHIBITOR
F2 inhibitor
Approval history
- approvedJun 30, 2000
Chemistry & pharmacology
SMILES
C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C2=CC=CC3=C2NCC(C)C3- Mol. weight
- 508.634 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaArgatroban ↗
- NCATSOCY3U280Y3 ↗
- ChEMBLCHEMBL1166 ↗
Also known as
- 2-piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-
- 4-methyl-1-(n(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl)-2-piperidinecarboxylic acid
- acova
- acova
- acova
- acova
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban
- argatroban hydrate
- argatroban in sodium chloride
- argatroban in sodium chloride
- argatroban monohydrate
- argatroban sodium
- dk-7419
- dk-7419
- gn1600
- gn1600
- gn-1600
- gn-1600
- mci 9038
- mci-9038
- mci-9038
- mci-9038
- md805
- md 805
- md-805
- md-805
- md-805
- mmtqap
- mpqa
- novastan
- novastan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06442267 | Phase 4 | Jul 30, 2024 | Medical University of Vienna |
| NCT05325346 | Phase 1 | Mar 7, 2022 | Celerion, Veralox Therapeutics |
| NCT05226442 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2021 | Medical University of Vienna |
| NCT04925167 | N/A | Jul 6, 2021 | Capital Medical University |
| NCT04406389 | Phase 4 | Jun 30, 2020 | Cornell University |
| NCT04275180 | Phase 4 | Feb 10, 2020 | Zhejiang University |
| NCT03735979 | Phase 3 | Jun 30, 2019 | National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati |
| NCT03809481 | Phase 3 | May 16, 2019 | Aspen Pharmaceuticals |
| NCT03740958 | Phase 4 | Dec 21, 2018 | People's Liberation Army of China |
| NCT03506009 | Phase 4 | Jul 11, 2018 | People's Liberation Army of China |
| NCT03552354 | Phase 4 | Oct 25, 2017 | People's Liberation Army of China |
| NCT05740371 | Phase 4 | Apr 18, 2017 | Mitsubishi Tanabe |
| NCT02935530 | Phase 3 | Jan 1, 2016 | Huazhong University of Science and Technology |
| NCT02448069 | Phase 2 | May 1, 2015 | University of Texas at Houston |
| NCT01911624 | Phase 2 | Jan 1, 2013 | Katholieke Universiteit Leuven |
| NCT01734252 | Phase 2 | Jun 1, 2012 | Medical University Innsbruck |
| NCT01464788 | Phase 2 | Oct 1, 2011 | The University of Texas Health Science Center, Houston, University of Texas at Houston |
| NCT01246011 | Phase 4 | Nov 1, 2010 | GlaxoSmithKline, Harvard University |
| NCT01163604 | Phase 4 | Aug 1, 2010 | Jinlin University, Nanjing University |
| NCT01980316 | Phase 4 | Apr 1, 2010 | Jinlin University, Nanjing University |
Organizations
Research & Development (27)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mitsubishi Tanabe | For profit | 4 | 3 | 3 | 2005 |
| People's Liberation Army of China | Government | 3 | 3 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 3 | 2 | 1 | 2003 |
| Encysive | For profit | 2 | 2 | 1 | 2002 |
| GlaxoSmithKline | For profit | 2 | 0 | 1 | 2003 |
| Jinlin University | Academic/Hospital | 2 | 2 | 1 | 2010 |
| Medical University of Vienna | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Mitsubishi | For profit | 2 | 0 | 1 | 2005 |
| Nanjing University | Academic/Hospital | 2 | 0 | 1 | 2010 |
| Aspen Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Celerion | For profit | 1 | 0 | 1 | 2022 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Government of Japan | Government | 1 | 1 | 1 | 2005 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Medical University Innsbruck | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Methodist Healthcare | Academic/Hospital | 1 | 1 | 1 | 2008 |
| National Cerebral and Cardiovascular Center | Government | 1 | 0 | 1 | 2005 |
Marketing (29)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Jun 7, 2021 |
| Accord Research | For profit | SYN | Jun 7, 2021 |
| Accord Research | For profit | NDA2 | Jun 7, 2021 |
| Amneal Pharmaceuticals | For profit | MKTG | Jan 26, 2018 |
| Aurobindo Pharma | For profit | NDA2 | Nov 27, 2018 |
| Baxalta | For profit | NDA2 | Jul 28, 2010 |
| Caplin Point Laboratories | For profit | MKTG | Jan 21, 2021 |
| Cipla | For profit | MKTG | Jun 29, 2011 |
| Cipla | For profit | NDA2 | Jun 29, 2011 |
| Eagle Pharmaceuticals, Inc. | For profit | NDA2 | Jun 29, 2011 |
| Encysive | For profit | NDA | — |
| Endo Pharmaceuticals | For profit | MKTG | Jun 30, 2014 |
| Eugia Pharma | For profit | MKTG | Nov 27, 2018 |
| Eugia Pharma | For profit | NDA2 | Nov 27, 2018 |
| Fosun | For profit | MKTG | Jul 31, 2023 |
| Fresenius | For profit | NDA2 | Mar 23, 2015 |
| Gland Pharma Ltd | For profit | MKTG | May 22, 2017 |
| Hikma | For profit | NDA2 | Jan 5, 2012 |
| Hospira | For profit | SYN | Sep 21, 2016 |
| Hospira | For profit | MKTG | Sep 21, 2016 |
| Mylan | For profit | MKTG | Jun 30, 2014 |
| Novartis | For profit | MKTG | Jun 30, 2000 |
| Novartis | For profit | NDA2 | Jun 30, 2000 |
| Par Pharmaceuticals | For profit | MKTG | Jun 30, 2014 |
| Pfizer | For profit | MKTG | Sep 21, 2016 |
| Pliva | For profit | MKTG | Dec 29, 2010 |
| Sandoz | For profit | NDA2 | May 9, 2011 |
| Teva | For profit | NDA2 | Dec 15, 2014 |
| Teva | For profit | MKTG | Dec 29, 2010 |